Neuro Devices Panel Skeptical On Alzheimer’s Treatment
Executive Summary
The US FDA neurological devices panel on March 21 found significant faults with Neuronix’s de novo application for its neuroAD Alzheimer’s treatment system. A key concern was that the device missed its primary endpoint in the pivotal trial.
You may also be interested in...
US FDA Panel Meeting Set For Alzheimer’s Device Treatment
An Alzheimer’s treatment device from Israeli firm Neuronix Ltd has landed a date with US FDA’s Neurological Devices Panel. The committee will discuss the neuroAD Therapy System on March 21.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
FDA Leader Looks To International Effort On Pediatric Device Development
Collaboration with Japan and Europe could help ease the development path for pediatric devices, cardiovascular device office director Bram Zuckerman said at a recent conference. Zuckerman also spoke on other cardiac device priorities at the FDA.